scholarly journals Point-of-care Ratiometric Fluorescence Imaging of Tissue for the Diagnosis of Ovarian Cancer

Theranostics ◽  
2019 ◽  
Vol 9 (16) ◽  
pp. 4597-4607 ◽  
Author(s):  
Xiaobo Zhou ◽  
Yawei Liu ◽  
Qiyu Liu ◽  
Luzhe Yan ◽  
Meng Xue ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1219
Author(s):  
Alisha R. Oropallo ◽  
Charles Andersen ◽  
Raymond Abdo ◽  
Jenny Hurlow ◽  
Martha Kelso ◽  
...  

Excessive levels of bacteria impede wound healing and can lead to infectious complications. Unfortunately, clinical signs and symptoms of elevated bacterial burden are often unreliable. As a result, point--of--care fluorescence imaging, used to detect critical bacterial burden in wounds, is becoming widely recognized and adopted by clinicians across the globe as an accepted and added component of wound assessment protocol. A Delphi method was employed to establish consensus guidelines describing fluorescence imaging use. A multidisciplinary panel of 32 wound experts (56% MD, 22% podiatrist, 12.5% nurses/nurse practitioners) representing multiple sites of service (e.g., hospital outpatient, inpatient, private office, long-term care) completed two rounds of online questionnaires. The Delphi included key topics, including competencies required to perform imaging, clinical indications for imaging (e.g., signs/symptoms present, procedures warranting imaging), frequency of imaging, and a clinical workflow algorithm. Describing their clinical experiences of imaging impact, >80% reported changes in treatment plans, 96% reported that imaging-informed treatment plans led to improved wound healing, 78% reported reduced rates of amputations, and 83% reported reduced rates of microbiological sampling. The guidelines provided here will help to standardize use of fluorescence imaging among wound care providers and enhance the quality of patient care.







2017 ◽  
Vol 89 (22) ◽  
pp. 12351-12359 ◽  
Author(s):  
Jin-Tao Yi ◽  
Ting-Ting Chen ◽  
Jia Huo ◽  
Xia Chu


Lab on a Chip ◽  
2011 ◽  
Vol 11 (20) ◽  
pp. 3411 ◽  
Author(s):  
ShuQi. Wang ◽  
Xiaohu Zhao ◽  
Imran Khimji ◽  
Ragip Akbas ◽  
Weiliang Qiu ◽  
...  


2011 ◽  
Vol 13 (11) ◽  
pp. 2799-2801 ◽  
Author(s):  
Gun-Joong Kim ◽  
Kiwon Lee ◽  
Hyockman Kwon ◽  
Hae-Jo Kim


Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3730
Author(s):  
Parsa Charkhchi ◽  
Cezary Cybulski ◽  
Jacek Gronwald ◽  
Fabian Oliver Wong ◽  
Steven A. Narod ◽  
...  

Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has been used as the primary ovarian cancer marker for the past four decades. The focus on diagnosing ovarian cancer in stages I and II using CA125 as a diagnostic biomarker has not improved patients’ survival. Therefore, screening average-risk asymptomatic women with CA125 is not recommended by any professional society. The dualistic model of ovarian cancer carcinogenesis suggests that type II tumours are responsible for the majority of ovarian cancer mortality. However, type II tumours are rarely diagnosed in stages I and II. The recent shift of focus to the diagnosis of low volume type II ovarian cancer in its early stages of evolution provides a new and valuable target for screening. Type II ovarian cancers are usually diagnosed in advanced stages and have significantly higher CA125 levels than type I tumours. The detection of low volume type II carcinomas in stage IIIa/b is associated with a higher likelihood for optimal cytoreduction, the most robust prognostic indicator for ovarian cancer patients. The diagnosis of type II ovarian cancer in the early substages of stage III with CA125 may be possible using a higher cutoff point rather than the traditionally used 35 U/mL through the use of point-of-care CA125 assays in primary care facilities. Rapid point-of-care testing also has the potential for effective longitudinal screening and quick monitoring of ovarian cancer patients during and after treatment. This review covers the role of CA125 in the diagnosis and management of ovarian cancer and explores novel and more effective screening strategies with CA125.



2020 ◽  
Vol 17 (8) ◽  
pp. 3140-3147 ◽  
Author(s):  
Kimberly Fung ◽  
Sai Kiran Sharma ◽  
Outi Keinänen ◽  
Kara Long Roche ◽  
Jason S. Lewis ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document